Sorry guys just like to squeeze in a comment or two regarding the trading halt. I assume this has been discussed ad nauseum today but too many posts to try and catch up on. I imagine that the halt is centered around MMJs activities in Australia concerning importation of medicinal cannabis products and possible licensing from the government. While this is very good news indeed, I'm not savvy with the pricing for such products and what "approval to sell and distribute" means for the company revenue wise. Any revenue is good revenue of course but I'm concerned that regardless of approval the income will be muted given it is not for orphan diseases and that there are other competitors in the market, or will be pending approval from the Australian govt. There is no doubt in my mind that legalization of marijuana in Canada will be massive for MMJ, but I think sales in Australia for capsules and the like wont translate to much in the share price overall. Does anyone else share this view?
Ann: Trading Halt, page-122
-
- There are more pages in this discussion • 73 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
